EU and US could reach trade deal this weekend - Reuters
Investing.com - RBC Capital raised its price target on Edwards Lifesciences (NYSE:EW) to $89.00 from $85.00 on Thursday, maintaining an Outperform rating following the company’s second-quarter earnings results. The stock, currently trading near its 52-week high of $83, has gained over 28% in the past year. InvestingPro analysis shows the company maintains a GOOD financial health score, with particularly strong profitability metrics.
Edwards Lifesciences reported second-quarter sales and earnings per share that exceeded expectations, with revenue surpassing forecasts by 3% and EPS beating estimates by 8%. The company delivered double-digit revenue growth for the first time in over a year, supported by an impressive 78.9% gross margin and 9.5% year-over-year revenue growth. For deeper insights into Edwards Lifesciences’ financial performance, InvestingPro subscribers can access the comprehensive Pro Research Report, which includes detailed analysis of key metrics and growth drivers.
The medical device maker raised the low end of its 2025 revenue guidance and expressed confidence in reaching the high end of its EPS forecast. The positive earnings report sent the stock up as much as 8% in after-hours trading.
RBC Capital cited multiple growth catalysts for Edwards, including TAVR (Transcatheter Aortic Valve Replacement) national coverage determination and market share capture, along with the ramp-up of its TMTT (Transcatheter Mitral and Tricuspid Therapies) business.
The investment bank expects these factors to drive consistent double-digit revenue and EPS growth for Edwards Lifesciences, supported by 50-100 basis points of annual operating margin expansion.
In other recent news, Edwards Lifesciences reported strong financial results for the second quarter of 2025. The company exceeded analysts’ expectations with an earnings per share (EPS) of $0.67, surpassing the forecasted $0.62. Additionally, Edwards Lifesciences achieved a revenue of $1.53 billion, which was above the anticipated $1.49 billion. Despite these positive earnings and revenue results, the company’s stock experienced a decline. There were no reports of mergers or acquisitions in the recent updates. Analyst firms have not issued any recent upgrades or downgrades for Edwards Lifesciences. These developments highlight the company’s financial performance in the recent quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.